QMS Medical FY26 Concall Decoded: ₹173 Crore Revenue, Minus the Profit Margin
General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.
1. Opening Hook
QMS Medical hit ₹173 crore in FY26 revenue—11% up year-on-year. But profit before tax fell to ₹16 crore from ₹19 crore. Management’s explainer: software development, data compliance, Saarathi integration, and hiring 850 out of 1,200 promised employees. The camps business pulled in ₹13 crore. The patient service programs—the “growth engine”—did the rest. By June, management had already committed to doubling services revenue in FY27, hired 850 people, and promised another 350–400 more. Everything’s on track, they said. Everything’s also eating margins.
2. At a Glance
Metric
Punchline
Revenue (FY26)
₹173 Cr, +11% YoY — half the pace of the ₹18% CAGR over three years
EBITDA (FY26)
₹26 Cr, +6% YoY — the growth whisper
PAT (FY26)
₹12 Cr (reported), down 16% — employees cost ₹15.2 Cr vs ₹9.6 Cr last year
Profit before tax
₹16 Cr (down from ₹19 Cr), despite revenue growth
Camps conducted
32,380 for the year; camps revenue ₹13 Cr (₹6,000–₹8,000 per camp)
Services mix
31% of revenue (₹50+ Cr); products 69% (₹120 Cr)
Services guidance (FY27)
Double revenue to ₹100 Cr; camps alone ₹18–₹20 Cr
EBITDA margin (services)
25% (locked in via contract); products 10–12%
FY27 revenue guidance
₹216 Cr (reiterated); EBITDA margin 18–19% target
Margin compression reason
Pre-loaded hiring and technology for new PSP contracts; benefit to appear in Q1 FY27 onwards
3. Management’s Key Commentary
Mahesh Makhija on the profit hit:
“We have put in a lot of money on it right now. We have increased the number of people — we have put a lot of money on the software development edge defining this year’s revenue.”
(Translation: Employees aren’t free. When you hire 850 people at once for a ₹50 crore services division, the timing mismatch is real. Contracts signed in December, billing starts April; the cost hits March.)
On DPDP Act compliance and data infrastructure:
“Data protection is required right now. There is within 18 months of period of time, every company who is into this data form has to be compliance in those angle right now. So we are already following those techniques right now, those systems.”
(Translation: Regulatory compliance is an investment line item now, not optional. ISO certification, data protection frameworks—all pre-loaded to unlock PSP contracts worth multiples of the cost.)
On the patient dropout problem (the core pitch):
“The patient when starts on a medicine drops off the medicine within first month itself only. What does it do the pharma company loses its customer… So what you do is basically with these type of programs, you help manage our pharma companies manage the patient, the patient sticks to the program, he adheres to all these medicines properly, which in case gives puts a less load on the healthcare actually.”
(Translation: Pharma companies lose customers in month one. QMS sells the infrastructure to keep them on therapy. The demand is real; the job is operational plumbing.)
On the Humrahi platform (Lupin’s patient support program):
“We are managing one of the leading healthcare programs of the industry, Humrahi right now with and Jai also right now for Lupin. We’re doing 7 different programs right now after the launch of GLP-1.”
(Translation: GLP-1 drugs (semaglutide, tirzepatide) have opened a new pharma spend category. Patient adherence matters now. QMS gets paid to manage the engagement.)
On competitive position vs. Practo:
“Practo is not in this, it is patient management practices, not dominating, I would not agree on that what they dominates, on those programs and services, I think QMS is doing much better than that.”
(Translation: Practo does general health-at-home; QMS does pharma-sponsored patient programs. Different market, same subject.)
On the camps-to-PSP shift:
“Our target obviously is to double the revenue what we have done this year in the services and patient service programs. And all these are obviously paid by the pharma company.”
(Translation: The business model is B2B2C. Pharma companies pay. Camps are transactional (₹6k–₹8k per event); PSPs are fixed-cost contracts with SLAs. One scales by event; the other scales by locked-in commitment.)
On Q4 revenue drop (H1: ₹91–92 Cr; H2: ₹70–74 Cr):
“In quarter 3 and quarter 4, we started seeing some disruptions in delay in orders also in delay in supply of materials. So that was the reason of the reduction and typically because of delays that we faced. And some part of that has been made up March orders, which have been pushed to April, May have come in.”
